Clinical Trial

Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)

Study acronym: PNP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2025 (before its estimated July 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare the effects of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals aged 15 to 29 years, with and without Hereditary Sensorimotor Polyneuropathy (HSPN). The main questions to answer are: What is the effect of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals with and without HSPN? Will the percentage of improvement after the program be greater in participants with HSPN compared to those without, due to greater baseline alterations? Researchers will compare the resistance exercise training program with baseline conditions to determine its effectiveness in improving skeletal muscle quality, functional capacity, and quality of life. Participants will undergo a supervised lower-limb resistance exercise program (3x/week) for 8 weeks. The intervention will include progressive loads from 60% to 80% of 1-Repetition Maximum (1RM), with exercises targeting the major lower limb muscle groups. All participants will complete pre- and post-intervention evaluations, including ultrasound assessment of muscle architecture, functional capacity tests, strength measurements, body composition analysis, and quality of life questionnaires.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2025-09-21
Trial Details
NCT Number NCT07152197
Lead Sponsor Universidad de La Frontera
Conditions Polyneuropathy, Charcot Marie Tooth Disease (CMT)
Enrollment 22 participants
Start Date 2025-09-20
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-09-20 (estimated)
Updated on ClinicalTrials.gov 2025-09-23